Effect of COMT Val108/158Met Genotype on Risk for Polydipsia in Chronic Patients with Schizophrenia
- 229 Downloads
Polydipsia is a serious condition often seen among patients with schizophrenia (SCZ). The cause of polydipsia is unknown; hence, it is hard to treat or manage. Animal studies showed that the drinking behavior is regulated by central dopaminergic neurotransmission at the hypothalamus. Meanwhile, the existence of a genetic predisposition to polydipsia in patients with SCZ has been suggested. The purpose of this study was to assess whether a functional polymorphism, Val108/158Met in the gene for catechol-O-methyltransferase (COMT), is associated with susceptibility to polydipsia using a Japanese sample of SCZ. Our sample includes 330 chronic patients with SCZ (83 polydipsic patients and 247 non-polydipsic controls). The common COMT Val108/158Met polymorphism was genotyped, and the differences in genotype distribution and allele frequency between cases and controls were evaluated using the χ 2 test. A significant association between the COMT Val108/158Met polymorphism and polydipsia was found (genotype distribution: χ 2 = 13.0, df = 2, p = 0.001; allele frequency: χ 2 = 7.50, df = 1, p = 0.006). The high-COMT activity group (Val/Val) was more frequent among patients with polydipsia compared with the low-COMT activity group (Val/Met + Met/Met) [odds ratio (OR) = 2.46]. The association survived after controlling for other possible confounding factors, including gender, age, age of onset, current antipsychotic dose, and smoking status. Our results suggest that the COMT Val108/158Met genotype may confer susceptibility to polydipsia in SCZ. To our knowledge, this is the first association study between the COMT gene and polydipsia in SCZ. Further studies with larger sample sizes are warranted to confirm present findings.
KeywordsPolydipsia Schizophrenia Catechol-O-methyltransferase Polymorphism Pharmacogenetics
This work was supported in part by Grant-in-Aid Number 18591319 for Scientific Research from the Ministry of Education, Science, Sports and Culture, Japan (TS), a grant from the Japanese Society of Schizophrenia Research (TS). The authors wish to thank Ms. Kyoko Hara from the Bio-information Research Center, University of Occupational and Environmental Health, Japan, for her technical support.
Conflict of interest
Professor Jun Nakamura has received Grant support from Astellas Pharma Inc., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Pfizer Japan Inc., Dainippon Sumitomo Pharma Co., Ltd., and Otsuka Pharmaceutical Co., Ltd. in 2012. Kenji Yamada, Takahiro Shinkai, Hsin-I Chen, and Kensuke Utsunomiya report no financial relationships with commercial interests.
- Egan, M. F., Goldberg, T. E., Kolachana, B. S., Callicott, J. H., Mazzanti, C. M., Straub, R. E., et al. (2001). Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proceedings of the National Academy of Sciences, 98(12), 6917–6922. doi: 10.1073/pnas.111134598.CrossRefGoogle Scholar
- Fukunaka, Y., Shinkai, T., Hwang, R., Hori, H., Utsunomiya, K., Sakata, S., et al. (2007). The orexin 1 receptor (HCRTR1) gene as a susceptibility gene contributing to polydipsia–hyponatremia in schizophrenia. Neuromolecular Medicine, 9(4), 292–297. doi: 10.1007/s12017-007-8001-2.PubMedCrossRefGoogle Scholar
- Lachman, H. M., Papolos, D. F., Saito, T., Yu, Y. M., Szumlanski, C. L., & Weinshilboum, R. M. (1996). Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics, 6(3), 243–250.PubMedCrossRefGoogle Scholar
- Matsumoto, C., Shinkai, T., De Luca, V., Hori, H., Hwang, R., Ohmori, O., et al. (2006). Association study between functional polymorphisms in the cytochrome P450 1A2 and 2D6 genes and polydipsia in schizophrenia. Neuromolecular Medicine, 8(3), 381–388. doi: 10.1385/NMM:8:3:381.PubMedCrossRefGoogle Scholar
- Shinkai, T., De Luca, V., Utsunomiya, K., Sakata, S., Inoue, Y., Fukunaka, Y., et al. (2008). Functional polymorphism of the human multidrug resistance gene (MDR1) and polydipsia–hyponatremia in schizophrenia. Neuromolecular Medicine, 10(4), 362–367. doi: 10.1007/s12017-008-8041-2.PubMedCrossRefGoogle Scholar
- Shinkai, T., Ohmori, O., Hori, H., & Nakamura, J. (2003). Genetic approaches to polydipsia in schizophrenia: A preliminary report of a family study and an association study of an angiotensin-converting enzyme gene polymorphism. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 119B(1), 7–12. doi: 10.1002/ajmg.b.10066.CrossRefGoogle Scholar
- Tan, H. Y., Chen, A. G., Chen, Q., Browne, L. B., Verchinski, B., Kolachana, B., et al. (2012). Epistatic interactions of AKT1 on human medial temporal lobe biology and pharmacogenetic implications. Molecular Psychiatry, 17(10), 1007–1016. doi: 10.1038/mp.2011.91.PubMedCentralPubMedCrossRefGoogle Scholar
- Vieweg, W. V., David, J. J., Rowe, W. T., Peach, M. J., Veldhuis, J. D., & Spradlin, W. W. (1986). Correlation of cigarette-induced increase in serum nicotine levels with arginine vasopressin concentrations in the syndrome of self-induced water intoxication and psychosis (SIWIP). Canadian Journal of Psychiatry, 31(2), 108–111.Google Scholar
- Yoshio, T., Inada, T., Uno, J., Miwa, T., Kitagawa, K., Miyahara, Y., et al. (2012). Prescription profiles for pharmacological treatment of Japanese inpatients with schizophrenia: Comparison between 2007 and 2009. Human Psychopharmacology, 27(1), 70–75. doi: 10.1002/hup.1272.PubMedCrossRefGoogle Scholar